New Data Confirm Biogen’s (BIIB) Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. MU
6. USO
7. APGE
8. ABBV
9. MSFT
10. IBM

Go back to New Data Confirm Biogen’s (BIIB) Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis

Biogen (BIIB) to Report Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS at American Neurological Association Annual Meeting

October 14, 2021 4:07 PM EDT

Biogen Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense oligonucleotide (ASO) drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), will be presented at the upcoming American Neurological Association (ANA) 2021 virtual meeting, October 17-19, 2021.

... More

Biogen (BIIB) PT Lowered to $447 at Morgan Stanley

October 12, 2021 2:41 AM EDT

Morgan Stanley analyst Matthew Harrison lowered the price target on Biogen (NASDAQ: BIIB) to $447.00 (from $455.00) while maintaining a Overweight rating.... More